Growth Story Still Intact For Integra LifeSciences Holdings Corporation (IART)

Boston Management & Research has recently announced that it has increased stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 3.65%. After grabbing 3.12 million shares, the institutional investor is now in possession of 0.11 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.81% having worth around $172.78 million. Moreover, AllianceBernstein LP increased its share by 36981.0 to have a control over 2.93 million shares. And ClearBridge Investments LLC raised its holdings to 0.16 million shares by acquiring 2.74 million shares or 3.35% of the stake.

Integra LifeSciences Holdings Corporation (IART) concluded trading on 05/25/23 at a closing price of $38.48, with 1.37 million shares of worth about $52.76 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -28.64% during that period and on Thursday the price saw a loss of about -1.71%. Currently the company’s common shares owned by public are about 81.87M shares, out of which, 72.65M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 14 analysts are covering the IART stock and their offered price forecasts bring an average price target of $51.60. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $65.00 and could fall to a lowest price of $39.00. The stock’s current price level is 32.96% above of average price target set by the analysts, while a rise to estimated low would result in gain of 1.33% for the stock. However, touching the estimated high of $65.00 would mean a gain of 40.8% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 83 times over the past 12 months. They bought 75,167 shares in 31 of the transactions. In 52 selling transactions, insiders dumped 212,391 shares.

American Funds Small Cap World Fu, Eaton Vance Tax Managed Growth Po, and iShares Core S&P Mid Cap ETF are the top 3 mutual funds which are holding stakes in Integra LifeSciences Holdings Corporation American Funds Small Cap World Fu is currently holding 3.3 million shares of worth totaling $182.32 million. The company recently came buying 0.0 shares which brought its stake up to 4.02% of the company’s outstanding shares. iShares Core S&P Mid Cap ETF, after buying 2.27 million shares, have now control over 2.77% of the stake in the company. It holds 7945.0 shares of worth $125.43 million.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) started trading at $38.89, below -$0.26 from concluding price of the previous day. However, the stock later moved at a day high price of 38.92, or with a loss of -1.71%. Stock saw a price change of -22.58% in past 5 days and over the past one month there was a price change of -29.00%. Year-to-date (YTD), IART shares are showing a performance of -31.37% which decreased to -35.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $39.00 but also hit the highest price of $62.99 during that period. The average intraday trading volume for Integra LifeSciences Holdings Corporation shares is 622.37K. The stock is currently trading -22.86% below its 20-day simple moving average (SMA20), while that difference is down -28.54% for SMA50 and it goes to -26.98% lower than SMA200.

Boston Management & Research acquired 3.12 million shares of Integra LifeSciences Holdings Corporation having value of about $172.78 million. Data submitted at the U.S SEC by Boston Management & Research revealed that the firm now holds 0.11 million shares in the company valued at close to $4230991.44, or have control over 3.65% stake in the company. Integra LifeSciences Holdings Corporation (NASDAQ: IART) currently have 81.87M outstanding shares and institutions hold larger chunk of about 91.60% of that. Holding of mutual funds in the company is about 32.29% while other institutional holders and individual stake holders have control over 57.52% and 21.18% of the stake respectively.

The stock has a current market capitalization of $3.15B and its 3Y-monthly beta is at 1.16. PE ratio of stock for trailing 12 months is 18.63, while it has posted earnings per share of $2.06 in the same period. Its PEG reads 2.66 and has Quick Ratio of 2.40 while making debt-to-equity ratio of 0.86. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IART, volatility over the week remained 5.51% while standing at 3.10% over the month.

Analysts are in expectations that Integra LifeSciences Holdings Corporation (IART) stock would likely to be making an EPS of $0.64 in the current quarter, while forecast for next quarter EPS is $0.87 and it is $3.69 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.56 which is $0.77 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $0.81 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 9.30% while it is estimated to increase by 10.41% in next year. EPS is likely to shrink at an annualized rate of 7.00% for next 5-years, compared to annual growth of 9.60% made by the stock over the past 5-years.

Analysts at 14 brokerage firms have issued recommendations for the Integra LifeSciences Holdings Corporation (IART)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.80. Out of those 14 Wall Street analysts, 3 recommended a “Buy” rating, while 7 were in favor recommending the stock as a “Hold” and 2 analyst recommended the stock as “Sell”.